Gyre Therapeutics, Inc. – NASDAQ:GYRE
Gyre Therapeutics stock price today
$7.52
-4.93
-39.6%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Gyre Therapeutics stock price monthly change
-7.23%
month
Gyre Therapeutics stock price quarterly change
-7.23%
quarter
Gyre Therapeutics key metrics
Market Cap | 1.04B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.11 |
Revenue | 114.02M |
EBITDA | 6.63M |
Income | -91.09M |
Revenue Q/Q | 11.19% |
Revenue Y/Y | 49.74% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 5.82% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGyre Therapeutics stock price history
Gyre Therapeutics stock forecast
Gyre Therapeutics financial statements
| Jun 2023 | 26.13M | 5.59M | 21.41% |
|---|---|---|---|
| Sep 2023 | 30.73M | -52.03M | -169.28% |
| Dec 2023 | 29.98M | -52.19M | -174.08% |
| Mar 2024 | 27.17M | 7.53M | 27.72% |
| 2025 | 84.81M | -19.74M | -23.29% |
|---|
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | 7.38% |
| 2023 |
| Jun 2023 | 12394000 | 40.70M | 328.45% |
|---|---|---|---|
| Sep 2023 | 9964000 | 6.44M | 64.7% |
| Dec 2023 | 116539000 | 38.06M | 32.66% |
| Mar 2024 | 122010000 | 33.23M | 27.24% |
| Jun 2023 | -2.47M | 4.79M | -3.5M |
|---|---|---|---|
| Sep 2023 | -3.21M | 1M | -1.47M |
| Dec 2023 | 4.02M | -776.14K | 1.38M |
| Mar 2024 | 2.88M | -7.22M | 658K |
Gyre Therapeutics alternative data
| Jun 2024 | 593 |
|---|---|
| Jul 2024 | 593 |
Gyre Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 20000 |
| Apr 2024 | 0 | 20000 |
| May 2024 | 0 | 20000 |
| Jun 2024 | 0 | 3452 |
| Dec 2024 | 0 | 4000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MA SONGJIANG director, officer: President | Common Stock | 1,571 | $11.17 | $17,548 | ||
Sale | MA SONGJIANG director, officer: President | Common Stock | 429 | $12.11 | $5,195 | ||
Sale | MA SONGJIANG director, officer: President | Common Stock | 1,212 | $10.94 | $13,259 | ||
Sale | MA SONGJIANG director, officer: President | Common Stock | 788 | $11.23 | $8,849 | ||
Sale | USMAN NASSIM director | Common Stock | 3,452 | $12 | $41,438 | ||
Option | USMAN NASSIM director | Stock Option (Right to Buy) | 3,452 | $6.93 | $23,922 | ||
Option | USMAN NASSIM director | Common Stock | 3,452 | $6.93 | $23,922 | ||
Option | USMAN NASSIM director | Stock Option (Right to Buy) | 20,000 | $6.93 | $138,600 | ||
Option | USMAN NASSIM director | Common Stock | 20,000 | $6.93 | $138,600 | ||
Sale | USMAN NASSIM director | Common Stock | 14,900 | $13.86 | $206,514 |
-
What's the price of Gyre Therapeutics stock today?
One share of Gyre Therapeutics stock can currently be purchased for approximately $7.52.
-
When is Gyre Therapeutics's next earnings date?
Unfortunately, Gyre Therapeutics's (GYRE) next earnings date is currently unknown.
-
Does Gyre Therapeutics pay dividends?
No, Gyre Therapeutics does not pay dividends.
-
How much money does Gyre Therapeutics make?
Gyre Therapeutics has a market capitalization of 1.04B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 14188.41% to 113.45M US dollars.
-
What is Gyre Therapeutics's stock symbol?
Gyre Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GYRE".
-
What is Gyre Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Gyre Therapeutics?
Shares of Gyre Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Gyre Therapeutics have?
As Jul 2024, Gyre Therapeutics employs 593 workers.
-
When Gyre Therapeutics went public?
Gyre Therapeutics, Inc. is publicly traded company for more then 19 years since IPO on 12 Apr 2006.
-
What is Gyre Therapeutics's official website?
The official website for Gyre Therapeutics is gyretx.com.
Gyre Therapeutics company profile:
Gyre Therapeutics, Inc.
gyretx.comExchange:
NASDAQ
Full time employees:
593
Industry:
Biotechnology
Sector:
Healthcare
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
,
CIK: 0001124105
ISIN: US4037831033
:
